What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis

What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis

Carmen Fucile,1 Francesca Mattioli,1 Valeria Marini,1 Massimo Gregori,2 Aurelio Sonzogni,3 Antonietta Martelli,1 Natalia Maximova4 1Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy; 2Department of Pediatric Radiology, Institute for Maternal and Child Health – IRCCS Burl...

Full description

Bibliographic Details
Main Authors:	Fucile C, Mattioli F, Marini V, Gregori M, Sonzogni A, Martelli A, Maximova N
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-09-01
Series:	Therapeutics and Clinical Risk Management
Subjects:	deferasirox allogeneic hematopoietic stem cell transplantation (allo-HSCT) pediatric ductopenia therapeutic drug monitoring adverse events
Online Access:	https://www.dovepress.com/what-is-known-about-deferasirox-chelation-therapy-in-pediatric-hsct-re-peer-reviewed-article-TCRM

Similar Items

Allogeneic HSCT in Adolescents and Young Adults With Primary Immunodeficiencies
by: Emma C. Morris, et al.
Published: (2019-10-01)

Donor and Recipient Individual Factors as Predictive Markers of Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation; Dream or Reality
by: Pooya Eslampour, et al.
Published: (2021-02-01)

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
by: Nancy Y. Villa, et al.
Published: (2016-03-01)

High Throughput Analysis Reveals Changes in Gut Microbiota and Specific Fecal Metabolomic Signature in Hematopoietic Stem Cell Transplant Patients
by: Soumaya Kouidhi, et al.
Published: (2021-08-01)

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
by: Ariadna Bartoló-Ibars, et al.
Published: (2021-09-01)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
by: Laura Galeotti, et al.
Published: (2021-08-01)

Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation
by: Hooi Ching Lim, et al.
Published: (2021-01-01)

Cytomegalovirus pneumonitis complicated by a central peribronchial pattern of organising pneumonia
by: Maria M. Cuadrado, et al.
Published: (2017-01-01)

Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma
by: Kunihiro Tsukasaki, et al.
Published: (2020-06-01)

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
by: Elena Maria Elli, et al.
Published: (2014-05-01)

Torque Teno Virus Viral Load as a Marker of Immune Function in Allogeneic Haematopoietic Stem Cell Transplantation Recipients
by: William Mouton, et al.
Published: (2020-11-01)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors
by: EV Morozova, et al.
Published: (2019-03-01)

The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma
by: Nadira Duraković, et al.
Published: (2021-07-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2020-07-01)

Low pre-transplant levels of mannose-binding lectin are associated with viral infections and mortality after haematopoietic allogeneic stem cell transplantation
by: M. Puente, et al.
Published: (2019-11-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR
by: Evy Sari Sutrisnaningsih, et al.
Published: (2017-08-01)

Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow
by: J.C. Shen, et al.
Published: (2017-10-01)

Economic Impact of Pharmacokinetic Monitoring on the use of Oral and Intravenous Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
by: Karpen, Stephen, et al.
Published: (2014)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
by: Andrzej Lange, et al.
Published: (2021-06-01)

Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells
by: Chiara Calabrese, et al.
Published: (2020-10-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase
by: Maryam Moradi, et al.
Published: (2014-11-01)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
by: Alba Rodríguez-García, et al.
Published: (2019-10-01)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
by: Giuseppe A. Palumbo, et al.
Published: (2021-10-01)

Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease
by: Xinyi Zhou, et al.
Published: (2020-04-01)

Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome
by: Hiroki Hosoi, et al.
Published: (2018-09-01)

High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
by: Zhang G, et al.
Published: (2019-04-01)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
by: Lv Meng, et al.
Published: (2012-03-01)

Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
by: MV Barabanshchikova, et al.
Published: (2016-07-01)

Results of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia with t(8;21)(q22;q22)/RUNX1-RUNX1T1 and Additional Cytogenetic Abnormalities
by: TL Gindina, et al.
Published: (2016-04-01)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
by: Hana Votavova, et al.
Published: (2021-01-01)

Pengaruh Deferasirox Terhadap Kadar T4 dan TSH Pada B-Thalassemia Mayor dengan Kadar Ferritin Tinggi
by: Dewi Ratih P, et al.
Published: (2016-11-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

Late Complications in acute Leukemia Patients following HSCT: A single center experience
by: Mohammad Vaezi, et al.
Published: (2016-04-01)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015-12-01)

Dangers resulting from DNA profiling of biological materials derived from patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with regard to forensic genetic analysis
by: Renata Jacewicz, et al.
Published: (2016-07-01)